Aug 08, 2018
Teva’s migraine drug is expected to launch this year despite the delay in FDA approval Teva Pharmaceutical’s fremanezumab for treating migraine is expected to launch later this year. Celltrion disclosed that U.S. drug regulators issued a Form 483 for its plant in Incheon, South Korea on tuesdsy. Eight manufacturin...
Read More...
Discover How Learning Disability Treatment Landscape is Evolving with the Emergence of Digital Assistant Technologies
Jul 04, 2025
A New Era for Multiple Myeloma Treatment: Bispecific Antibodies Enter the Fray
Jun 10, 2025
LEQEMBI: A New Hope for Alzheimer’s Disease Patients
Feb 12, 2025
-Agonist.png "Toll-like Receptors Agonist")
Newsletter/Whitepaper